Nichi-Iko Pharmaceutical
Biosimilar developer, Japan. 2 development products across 2 molecules: bevacizumab, infliximab.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab | Bevacizumab BS Nichi-Iko | · | · | · | Jan 2022 | · | · | · | 1/7 |
| Infliximab | Infliximab BS Nichiiko / AYUMI | · | · | · | Sep 2017 | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Nichi-Iko Pharmaceutical is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Etanercept | Etanercept BS TY / Nichiiko | PMDA | Yoshindo; Nichi-Iko Pharmaceutical | Mar 2019 | Lupin |
Companies on the same molecules
Developers whose portfolios overlap most with Nichi-Iko Pharmaceutical, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- PMDASep 2017Infliximab BS Nichiiko / AYUMI, infliximab
- PMDAJan 2022Bevacizumab BS Nichi-Iko, bevacizumab
Compare Nichi-Iko Pharmaceutical with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant